Results 231 to 240 of about 4,771,800 (345)
An expanded STIRPAT model analysis of China's carbon neutrality pathways. [PDF]
Tshiaba SM, Liao G.
europepmc +1 more source
Chlorella vulgaris biorefineries: sustainable biofuels and high‐value carbon capture
Abstract Global reliance on fossil fuels has created urgent economic and environmental challenges, yet large‐scale use of algal biomass remains limited by production costs. Industrial scaling is constrained by inefficient harvesting and the technical challenges of processing recalcitrant cell walls.
Sandyelle Ferreira Alcântara Araújo +13 more
wiley +1 more source
Retraction notice to "Analyzing the influence of financial technology and environmental taxation on energy transformation in BRI nations" [Heliyon 10 (2024) e40635]. [PDF]
Zou Y, Ma N.
europepmc +1 more source
Abstract This study presents a novel bioeconomy optimization framework, BiOpt, designed to address critical questions regarding the strategic use of limited US biomass resources for biofuel production. By integrating detailed techno‐economic analyses, life cycle assessments, and resource assessment data, BiOpt optimizes resource distributions across ...
Nicholas A. Carlson +3 more
wiley +1 more source
Equity impacts of price policies to promote healthy behaviours.
F. Sassi +9 more
semanticscholar +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Bridging the regulatory gap: a call for a regional, evidence-informed approach to e-cigarette control in Latin America. [PDF]
Izquierdo-Condoy JS.
europepmc +1 more source
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source
Strengthening the use of regulatory policy measures for prevention of NCDs in Europe through the JA PreventNCD project. [PDF]
Helleve A +17 more
europepmc +1 more source

